VLA4-Enhanced Allogeneic Endothelial Progenitor Cell-Based Therapy Preserves the Aortic Valve Function in a Mouse Model of Dyslipidemia and Diabetes
- Supplementary File 1:
ZIP-Document (ZIP, 158 KiB)
Filippi, A.; Constantin, A.; Alexandru, N.; Mocanu, C.A.; Vlad, M.L.; Fenyo, I.M.; Simionescu, A.; Simionescu, D.T.; Manduteanu, I.; Georgescu, A. VLA4-Enhanced Allogeneic Endothelial Progenitor Cell-Based Therapy Preserves the Aortic Valve Function in a Mouse Model of Dyslipidemia and Diabetes. Pharmaceutics 2022, 14, 1077. https://doi.org/10.3390/pharmaceutics14051077
Filippi A, Constantin A, Alexandru N, Mocanu CA, Vlad ML, Fenyo IM, Simionescu A, Simionescu DT, Manduteanu I, Georgescu A. VLA4-Enhanced Allogeneic Endothelial Progenitor Cell-Based Therapy Preserves the Aortic Valve Function in a Mouse Model of Dyslipidemia and Diabetes. Pharmaceutics. 2022; 14(5):1077. https://doi.org/10.3390/pharmaceutics14051077
Chicago/Turabian StyleFilippi, Alexandru, Alina Constantin, Nicoleta Alexandru, Cristina A. Mocanu, Mihaela L. Vlad, Ioana M. Fenyo, Agneta Simionescu, Dan T. Simionescu, Ileana Manduteanu, and Adriana Georgescu. 2022. "VLA4-Enhanced Allogeneic Endothelial Progenitor Cell-Based Therapy Preserves the Aortic Valve Function in a Mouse Model of Dyslipidemia and Diabetes" Pharmaceutics 14, no. 5: 1077. https://doi.org/10.3390/pharmaceutics14051077